Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02252653
Recruitment Status : Completed
First Posted : September 30, 2014
Last Update Posted : July 20, 2016
Sponsor:
Information provided by (Responsible Party):
Alnylam Pharmaceuticals

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to characterize the frequency of TTR mutations in subjects suspected of having cardiac amyloidosis

Condition or disease
Familial Amyloidotic Cardiomyopathy (FAC)

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Actual Enrollment : 1010 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis
Study Start Date : June 2014
Actual Primary Completion Date : January 2016
Actual Study Completion Date : March 2016

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort
Familial Amyloidotic Cardiomyopathy (FAC)


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Proportion of patients with of Transthyretin (TTR) mutations [ Time Frame: Baseline ]
    Blood will be sequenced for the presence of TTR gene mutations


Secondary Outcome Measures :
  1. Assessment of the presence of amyloid in tissue [ Time Frame: Day 30 ]
    An optional fine-needle aspirate of the abdominal fat pad will be collected

  2. Quantification of biomarkers of cardiac function in serum [ Time Frame: Day 30 ]
    Biomarkers that assess cardiac function will be quantified from serum

  3. Measurement of echocardiogram parameters [ Time Frame: Day 30 ]
    Cardiac structure and function will be measured by echocardiogram

  4. New York Heart Association (NYHA) Functional Classification [ Time Frame: Day 30 ]
    NYHA Functional Classification will be determined

  5. Results from 6-Minute Walk Test [ Time Frame: Day 30 ]
    Total distance walked in 6 minutes will be measured


Biospecimen Retention:   Samples Without DNA
Blood samples for TTR sequencing and cardiac function biomarkers; abdominal fat-pad aspirate for amyloid presence (optional for TTR positive patients only)

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Subjects Suspected of Having Familial Amyloidotic Cardiomyopathy (FAC)
Criteria

Inclusion Criteria:

  • Males or females >18 years old
  • History of evidence suggestive of cardiac amyloidosis
  • Subject is willing and able to comply with protocol required assessments and provide written informed consent

Exclusion Criteria:

  • Known diagnosis of primary (AL) amyloidosis
  • Known diagnosis of hereditary cardiomyopathy or cardiomyopathy due to aortic stenosis
  • Patient is currently pregnant
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02252653


Locations
Show Show 58 study locations
Sponsors and Collaborators
Alnylam Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Jared Gollob, MD Alnylam Pharmaceuticals
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Alnylam Pharmaceuticals
ClinicalTrials.gov Identifier: NCT02252653    
Other Study ID Numbers: ALN-TTR-NT-002
First Posted: September 30, 2014    Key Record Dates
Last Update Posted: July 20, 2016
Last Verified: July 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Keywords provided by Alnylam Pharmaceuticals:
Cardiomyopathy
Heart Failure
FAC
Amyloid
Transthyretin (TTR)
Additional relevant MeSH terms:
Layout table for MeSH terms
Cardiomyopathies
Amyloidosis
Heart Diseases
 Cardiovascular Diseases
Proteostasis Deficiencies
Metabolic Diseases